文献速递胸部肿瘤

Serplulimab一线治疗广泛期小细胞肺癌:ASTRUM-005 3期随机临床试验二次分析

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

该研究为ASTRUM-005 3期随机双盲试验的预设二次分析,纳入585例初治广泛期小细胞肺癌患者,随机2:1接受Serplulimab或安慰剂联合卡铂/依托泊苷,中位随访42.4个月。

要点

  • Serplulimab联合化疗较安慰剂显著改善初治ES-SCLC的OS(15.8 vs 11.1个月,HR 0.60)
  • 4年OS率Serplulimab组21.9% vs 安慰剂组7.2%,显示长期生存获益
  • ≥3级治疗相关不良事件发生率Serplulimab组35.0% vs 安慰剂组29.1%

核心结论

  • 在初治广泛期小细胞肺癌中,Serplulimab联合化疗较安慰剂联合化疗显示长期生存获益,支持其作为一线标准治疗。

研究设计与样本

  • 国际、双盲、3期随机临床试验,2019年9月12日至2021年4月27日在中国、俄罗斯、乌克兰、波兰、土耳其和格鲁吉亚入组患者。
  • 纳入组织学或细胞学确诊、无既往系统治疗的ES-SCLC患者,按2:1随机接受Serplulimab 4.5 mg/kg或安慰剂联合最多4周期卡铂和依托泊苷(每3周一次)。
  • 共585例患者,Serplulimab组389例(66.5%),安慰剂组196例(33.5%);中位随访42.4个月(范围0.2-55.2)。

主要发现

  • 4年OS率Serplulimab组为21.9%,安慰剂组为7.2%。
  • ≥3级Serplulimab相关或安慰剂相关治疗中出现的不良事件分别发生于136例(35.0%)和57例(29.1%)。
  • 患者报告结局分析显示两组总体健康状况、呼吸困难和疼痛均呈一致改善趋势,Serplulimab组脱发恢复更快。

临床怎么用

  • 对于初治ES-SCLC患者,可考虑Serplulimab联合卡铂和依托泊苷作为一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The ASTRUM-005 phase 3 randomized clinical trial showed substantial survival benefit from adding serplulimab to chemotherapy for previously untreated extensive-stage small cell lung cancer (ES-SCLC). However, the long-term outcomes are unclear. OBJECTIVE: To investigate the efficacy, safety, patient-reported outcomes (PROs), and exploratory biomarker findings from ASTRUM-005 at an extended follow-up. DESIGN, SETTING, AND PARTICIPANTS: This international, double-blind, phase 3 randomized clinical trial enrolled patients from September 12, 2019, to April 27, 2021 in China, Russia, Ukraine, Poland, Turkey, and Georgia. Eligible patients had histologically or cytologically confirmed ES-SCLC with no prior systemic therapy. Patients were followed up through May 7, 2024, and the data analysis of this prespecified, secondary analysis lasted from August to September 2024. The median follow-up duration was 42.4 months (range, 0.2-55.2). EXPOSURES: Patients were randomized in a 2:1 ratio to receive intravenous serplulimab (4.5 mg/kg; serplulimab group) or placebo (placebo group), which was combined with up to 4 cycles of carboplatin and etoposide every 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points included other efficacy end points, safety, and PROs. RESULTS: A total of 585 patients (median [range] age was 63 [28-76] years in the serplulimab group and 62 [31-83] years in the placebo group) with previously untreated ES-SCLC, and 389 (66.5%) were randomly assigned to the serplulimab group and 196 (33.5%) to the placebo group. Baseline characteristics were balanced across treatment groups. At data cutoff, 280 OS events (72.0%) in the serplulimab group and 166 (84.7%) in the placebo group were observed. Compared with the placebo group, the serplulimab group showed more favorable efficacy (median OS, 15.8 [95% CI, 13.9-17.4] vs 11.1 [95% CI, 10.0-12.4] months; hazard ratio, 0.60; 95% CI, 0.49-0.73; P < .001). The serplulimab group showed improved OS rates at 4 years compared with the placebo group (21.9% vs 7.2%). Grade 3 or higher serplulimab-related or placebo-related treatment-emergent adverse events occurred for 136 (35.0%) and 57 patients (29.1%) in the respective groups. A PRO analysis revealed consistent trends of improved overall health, dyspnea, and pain in both groups and faster recovery from alopecia in the serplulimab group. CONCLUSIONS AND RELEVANCE: This secondary analysis of a randomized clinical trial demonstrated long-term benefit from adding serplulimab to chemotherapy for previously untreated patients with ES-SCLC, supporting this therapy as a first-line standard of care for this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04063163.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Liu J, Han L, Wu L, et al. First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42240984. doi:10.1001/jamaoncol.2026.1645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。